Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study

BACKGROUND: Mold-active primary antifungal prophylaxis (PAP) is routinely recommended in neutropenic patients with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) undergoing remission-induction chemotherapy (RIC). Isavuconazole (ISAV) is an extended spectrum...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Clin Infect Dis
Autores principales: Bose, Prithviraj, McCue, David, Wurster, Sebastian, Wiederhold, Nathan P, Konopleva, Marina, Kadia, Tapan M, Borthakur, Gautam, Ravandi, Farhad, Masarova, Lucia, Takahashi, Koichi, Estrov, Zeev, Yilmaz, Musa, Daver, Naval, Pemmaraju, Naveen, Naqvi, Kiran, Rausch, Caitlin R, Marx, Kayleigh R, Qiao, Wei, Huang, Xuelin, Bivins, Carol A, Pierce, Sherry A, Kantarjian, Hagop M, Kontoyiannis, Dimitrios P
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2020
Materias:
Major Articles and Commentaries
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8130026/
https://ncbi.nlm.nih.gov/pubmed/32236406
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/ciaa358
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares